|
1
|
Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium.
|
Am J Hum Genet
|
2007
|
3.31
|
|
2
|
The unrecognized prevalence of chronic kidney disease in diabetes.
|
Nephrol Dial Transplant
|
2005
|
2.24
|
|
3
|
Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study.
|
Lancet
|
2002
|
2.12
|
|
4
|
Pro-active call center treatment support (PACCTS) to improve glucose control in type 2 diabetes: a randomized controlled trial.
|
Diabetes Care
|
2005
|
1.20
|
|
5
|
Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans.
|
Am J Physiol Endocrinol Metab
|
2002
|
1.14
|
|
6
|
Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
1.04
|
|
7
|
Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial.
|
Diabetes Care
|
2005
|
1.03
|
|
8
|
Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways.
|
J Biol Chem
|
2004
|
1.03
|
|
9
|
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
|
J Card Fail
|
2010
|
0.98
|
|
10
|
C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups.
|
Atherosclerosis
|
2003
|
0.98
|
|
11
|
Significant ethnic variation in total and free testosterone concentration.
|
Clin Endocrinol (Oxf)
|
2003
|
0.92
|
|
12
|
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
|
Am J Cardiol
|
2007
|
0.92
|
|
13
|
Low circulating IGF-II concentrations predict weight gain and obesity in humans.
|
Diabetes
|
2003
|
0.91
|
|
14
|
Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization.
|
J Biol Chem
|
2011
|
0.90
|
|
15
|
Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes.
|
Diabetes
|
2002
|
0.85
|
|
16
|
Patient perceptions of treatment and illness when prescribed multiple medicines for co-morbid type 2 diabetes.
|
Diabetes Metab Syndr Obes
|
2011
|
0.84
|
|
17
|
IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes.
|
Endocr Connect
|
2012
|
0.84
|
|
18
|
Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes.
|
Diabetes
|
2005
|
0.83
|
|
19
|
Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable.
|
J Cell Mol Med
|
2008
|
0.81
|
|
20
|
The maternal environment programs postnatal weight gain and glucose tolerance of male offspring, but placental and fetal growth are determined by fetal genotype in the Leprdb/+ model of gestational diabetes.
|
Endocrinology
|
2015
|
0.78
|
|
21
|
Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes.
|
Am J Med
|
2006
|
0.78
|
|
22
|
Atorvastatin administration is associated with dose-related changes in IGF bioavailability.
|
Eur J Endocrinol
|
2013
|
0.75
|